Table 3 ILD subjects—clinical features and treatment
|  | Isolated ILD (N = 18) | PM/DM-ILD (N = 13) | p |
|---|---|---|---|
FVC % predicted—mean (± SD) | 71.5 (± 21.1) | 72.3 (± 22.5) | 0.93 |
DLCO % predicted—mean (± SD) | 49.7 (± 16.6) | 64.4 (± 29.3) | 0.15 |
CT features—mean (± SD) |  |  |  |
Ground glass | 1.44 (± 0.86) | 1.15 (± 0.80) | 0.35 |
Consolidation | 0.17 (± 0.51) | 0.38 (± 0.77) | 0.35 |
Reticulation | 2.17 (± 0.79) | 1.31 (± 0.63) | 0.0029 |
Traction | 1.89 (± 0.90) | 0.92 (± 0.86) | 0.0055 |
Fulminant ILD—no. (%) | 6 (33) | 2 (15) | 0.41 |
Serum CK, IU/L—median (range) | 75 (24–240) | 265 (82–8015) | 0.0001 |
Antisynthetase antibodies—no. (%) | 3 (17) | 12 (92) |  < 0.0001 |
Treatment—no (%) | 11 (65) | 13 (100) | 0.024 |
Prednisone | 11 (65) | 11 (85) | 0.41 |
Immunomodulators | 5 (29) | 12 (92) | 0.0008 |